Tags : (STS)

Pharma

Taiwan Liposome’s TLC178 Receives EMA’s ODD for Soft Tissue Sarcoma

Shots: The ODD follows P-I/II study assessing TLC178 in patients with advanced malignancies in adults and has resulted in no dose-limiting toxicity till date The EMA’s Orphan Drug Designation (ODD) is granted to the therapies offering life-threatening condition affecting ≤5 in 10,000 persons in EU, with no approved treatment and receiving 10-year of marketing exclusivity […]Read More